Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression
Neuronetics (NASDAQ: STIM) announced that Evernorth Health Services, a Cigna subsidiary, has expanded coverage of NeuroStar® Transcranial Magnetic Stimulation (TMS) to include adolescents aged 15 and older with major depressive disorder (MDD). This expansion, effective immediately, impacts 15 million covered lives.
The coverage update follows NeuroStar's FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. Several major insurers, including Humana, Aetna, and Medi-Cal, have updated their policies in response to this clearance.
The expansion addresses a significant need, as approximately 4.3 million U.S. adolescents aged 15-21 are affected by major depression. NeuroStar TMS offers a non-drug treatment option that can be used as a first-line add-on therapy with proven clinical outcomes.
Neuronetics (NASDAQ: STIM) ha annunciato che Evernorth Health Services, una sussidiaria di Cigna, ha ampliato la copertura della Stimolazione Magnetica Transcranica NeuroStar® (TMS) per includere gli adolescenti di età pari o superiore a 15 anni affetti da disturbo depressivo maggiore (MDD). Questa espansione, efficace immediatamente, interessa 15 milioni di persone coperte.
L'aggiornamento della copertura segue l'approvazione della FDA per NeuroStar come primo trattamento aggiuntivo di prima linea per gli adolescenti di età compresa tra 15 e 21 anni con MDD. Diversi importanti assicuratori, tra cui Humana, Aetna e Medi-Cal, hanno aggiornato le loro politiche in risposta a questa approvazione.
L'espansione risponde a un bisogno significativo, poiché circa 4,3 milioni di adolescenti statunitensi di età compresa tra 15 e 21 anni sono colpiti da depressione maggiore. La TMS di NeuroStar offre un'opzione di trattamento non farmacologico che può essere utilizzata come terapia aggiuntiva di prima linea con risultati clinici comprovati.
Neuronetics (NASDAQ: STIM) anunció que Evernorth Health Services, una subsidiaria de Cigna, ha ampliado la cobertura de la Estimulación Magnética Transcraneal NeuroStar® (TMS) para incluir a adolescentes de 15 años o más con trastorno depresivo mayor (MDD). Esta expansión, efectiva de inmediato, afecta a 15 millones de vidas cubiertas.
La actualización de la cobertura sigue a la aprobación de la FDA de NeuroStar como el primer tratamiento adicional de primera línea para adolescentes de 15 a 21 años con MDD. Varios importantes aseguradores, incluidos Humana, Aetna y Medi-Cal, han actualizado sus políticas en respuesta a esta aprobación.
La expansión aborda una necesidad significativa, ya que aproximadamente 4.3 millones de adolescentes estadounidenses de 15 a 21 años se ven afectados por la depresión mayor. La TMS de NeuroStar ofrece una opción de tratamiento no farmacológico que puede utilizarse como terapia adicional de primera línea con resultados clínicos comprobados.
Neuronetics (NASDAQ: STIM)는 Cigna의 자회사인 Evernorth Health Services가 주요 우울 장애(MDD)가 있는 15세 이상의 청소년을 포함하도록 NeuroStar® 경두개 자기 자극(TMS)의 보장을 확대했다고 발표했습니다. 이 확장은 즉시 시행되며, 1500만 명의 보장된 생명에 영향을 미칩니다.
보장 업데이트는 15세에서 21세 사이의 청소년을 위한 첫 번째 추가 1차 치료법으로서 NeuroStar의 FDA 승인을 따릅니다. Humana, Aetna 및 Medi-Cal을 포함한 여러 주요 보험사들이 이 승인을 반영하여 정책을 업데이트했습니다.
이 확장은 약 430만 명의 미국 청소년(15-21세)이 주요 우울증에 영향을 받고 있는 중대한 필요를 해결합니다. NeuroStar TMS는 입증된 임상 결과와 함께 1차 추가 요법으로 사용할 수 있는 비약물 치료 옵션을 제공합니다.
Neuronetics (NASDAQ: STIM) a annoncé qu'Evernorth Health Services, une filiale de Cigna, a élargi la couverture de la Stimulation Magnétique Transcrânienne NeuroStar® (TMS) pour inclure les adolescents de 15 ans et plus souffrant de trouble dépressif majeur (MDD). Cette expansion, effective immédiatement, concerne 15 millions de vies couvertes.
La mise à jour de la couverture fait suite à l'approbation de la FDA de NeuroStar en tant que premier traitement supplémentaire de première ligne pour les adolescents âgés de 15 à 21 ans souffrant de MDD. Plusieurs grands assureurs, dont Humana, Aetna et Medi-Cal, ont mis à jour leurs politiques en réponse à cette approbation.
Cette expansion répond à un besoin significatif, car environ 4,3 millions d'adolescents américains âgés de 15 à 21 ans sont touchés par une dépression majeure. La TMS de NeuroStar offre une option de traitement non médicamenteux qui peut être utilisée comme thérapie supplémentaire de première ligne avec des résultats cliniques prouvés.
Neuronetics (NASDAQ: STIM) gab bekannt, dass Evernorth Health Services, eine Tochtergesellschaft von Cigna, die Abdeckung der NeuroStar® Transkranielle Magnetstimulation (TMS) erweitert hat, um Jugendliche ab 15 Jahren mit einer Major Depression (MDD) einzuschließen. Diese Erweiterung tritt sofort in Kraft und betrifft 15 Millionen versicherte Personen.
Das Update der Abdeckung folgt auf die FDA-Zulassung von NeuroStar als erste Zusatzbehandlung der ersten Linie für Jugendliche im Alter von 15 bis 21 Jahren mit MDD. Mehrere große Versicherer, darunter Humana, Aetna und Medi-Cal, haben ihre Richtlinien als Reaktion auf diese Genehmigung aktualisiert.
Die Erweiterung adressiert einen erheblichen Bedarf, da etwa 4,3 Millionen US-Jugendliche im Alter von 15 bis 21 Jahren von schwerer Depression betroffen sind. NeuroStar TMS bietet eine nicht-medikamentöse Behandlungsoption, die als Zusatztherapie der ersten Linie mit nachgewiesenen klinischen Ergebnissen eingesetzt werden kann.
- Expanded insurance coverage to 15 million additional lives
- FDA clearance as first first-line add-on treatment for adolescents
- Multiple major insurers adding coverage, expanding market reach
- Large addressable market of 4.3 million affected adolescents
- None.
Insights
Evernorth Health Services' policy update to include NeuroStar TMS coverage for adolescents 15+ with major depression represents a significant commercial breakthrough for Neuronetics. This expands accessible treatment to approximately
The timing is strategic - occurring just one year after NeuroStar's FDA clearance as the first first-line add-on treatment for adolescents with MDD. This rapid payor adoption pattern is particularly notable, with major insurers like Humana, Aetna, and several Blue Cross entities already updating coverage policies. Such quick payor momentum typically indicates strong clinical evidence and growing provider demand.
The commercial opportunity is substantial. With an estimated 4.3 million U.S. adolescents affected by major depression, and medication options for this population, Neuronetics is targeting an underserved therapeutic gap. The company's dedicated health policy team represents a strategic advantage in accelerating coverage expansion across other insurers and potentially positioning for additional reimbursement categories.
This policy update materially strengthens Neuronetics' market position in neuromodulation for adolescent psychiatry while creating immediate commercial tailwinds. As the first mover with payor coverage in this demographic, they've established competitive barriers against other TMS providers while expanding their total addressable market.
This Evernorth coverage expansion for NeuroStar TMS therapy in adolescents aged 15+ establishes Neuronetics as the clear frontrunner in non-pharmacological depression treatments for younger patients. The policy change transforms NeuroStar from an adult-only therapy to a cross-demographic platform with significantly expanded revenue potential.
From a competitive standpoint, Neuronetics has executed a textbook market development strategy: first securing FDA clearance for adolescents (aged 15-21), then rapidly converting that regulatory win into commercial coverage policies. Their dedicated payor-focused team has delivered impressive results, with multiple major insurers adopting coverage in under 12 months.
The technical advantage here shouldn't be overlooked. Neuronetics explicitly positions NeuroStar as having "the most comprehensive data" for adolescent MDD treatment. In medical technology, especially psychiatric applications, establishing this evidence leadership creates powerful differentiation from competitors seeking to enter the same space.
What makes this particularly meaningful is the intersection of clinical need and market opportunity. The adolescent psychiatric market has remarkably few FDA-cleared non-drug options, creating a potential therapy vacuum that Neuronetics can fill. With depression affecting academic performance and overall development, the value proposition to adolescent patients (and by extension, their families and providers) is compelling. The expanded insurance coverage removes the final major barrier to adoption.
Policy update increases access for millions covered by Evernorth Health Services
MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, announced that Evernorth Health Services, a wholly owned subsidiary of The Cigna Group, has expanded its coverage of NeuroStar® Transcranial Magnetic Stimulation (TMS) to include adolescents aged 15 and older living with major depressive disorder (MDD). As these health policies cover 15 million lives, the expansion greatly improves access to non-drug treatment options for adolescent patients who are seeking non-drug options for depression.
The expansion is effective immediately, nearly one year after NeuroStar® Advanced Therapy received FDA clearance as the first first-line add-on treatment for adolescents aged 15-21 with MDD. In the past year, several leading insurers have rapidly updated their policies to reflect the FDA clearance, including but not limited to Humana, Aetna, Medi-Cal, BCBS-HCSC, Pacific Source, and more.
“This decision by Cigna/Evernorth is a significant step forward for adolescent mental healthcare and reflects the momentum we have built with payors over the past year since NeuroStar first received the FDA clearance for adolescents,” said Keith J. Sullivan, President and CEO of Neuronetics. “We are grateful that millions more families will now have easier access to NeuroStar TMS as a proven, non-drug treatment for major depression and can get the care they deserve.”
An estimated 4.3 million U.S. adolescents aged 15-21 are affected by major depression1. Depression amongst adolescents can disrupt crucial aspects of development, such as academic performance, relationships with peers and family members, and overall emotional well-being. With limited medication options for adolescents with MDD, NeuroStar is a safe and effective option that can be used as a first-line add-on with robust clinical outcomes.
“NeuroStar stands as the leading TMS device, backed by the most comprehensive data that clearly demonstrates its effectiveness in treating adolescent major depressive disorder,” said Geoffrey Grammer, MD, Chief Medical Officer of Neuronetics. “At Neuronetics, we are deeply committed to putting patients first, advancing clinical research, and ensuring that those in need have access to life-changing, innovative solutions.”
Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy updates.
For more information about NeuroStar Advanced Therapy, please visit www.neurostar.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.1 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes database. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.68 million treatments to over 51,000 patients struggling with depression.
The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.
Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
References
- World Health Organization, Depression Fact Sheet. Accessed April 29, 2024. https://www.who.int/news-room/fact-sheets/detail/depression.
________________________________
* The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com.
FAQ
What is the impact of Evernorth Health Services' coverage expansion for STIM's NeuroStar TMS?
Which major insurance companies have approved NeuroStar TMS coverage for adolescents in 2024-2025?
What age group received FDA clearance for NeuroStar TMS treatment?
How many adolescents could potentially benefit from STIM's NeuroStar TMS treatment?
